Voreloxin

Manufactured by Selleck Chemicals

Sourced in United States

Voreloxin is a small molecule compound used in laboratory research. It functions as a topoisomerase II inhibitor, disrupting the activity of this enzyme that is essential for DNA replication and cell division.

Automatically generated - may contain errors

Lab products found in correlation

Vx 11e, by Selleck Chemicals (1 mentions) Docetaxel, by Selleck Chemicals (1 mentions) Etoposide, by Selleck Chemicals (1 mentions) Mln4924, by Selleck Chemicals (1 mentions) Doxorubicin, by Selleck Chemicals (1 mentions) Sn 38, by Selleck Chemicals (1 mentions) Cycloheximide chx n11534, by Merck Group (1 mentions) Bortezomib, by Selleck Chemicals (1 mentions) Mg132, by Selleck Chemicals (1 mentions)

2 protocols using voreloxin

Preparation of VX-11e and Voreloxin

Check if the same lab product or an alternative is used in the 5 most similar protocols

VX-11e and voreloxin were purchased form Selleck Chemicals (Selleckchem, Houston, TX, USA). Stock solutions of drugs were dissolved in DMSO, aliquoted and kept frozen at − 80 °C until use.

Jasek-Gajda E., Jurkowska H., Jasińska M., Litwin J.A, & Lis G.J. (2019). Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells. Apoptosis, 24(11), 849-861.

+ Open protocol

+ Expand

Immunoblotting analysis of drug-treated cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Drugs used in the study include: Bortezomib (S1013), MLN4924 (S7109), MG132 (S2619), Docetaxel (S1148), Doxorubicin (S1208), Etoposide (S1255), SN‐38 (S4908), and Voreloxin (S7518) from Selleckchem. Cycloheximide (CHX; N11534) was purchased from Sigma‐Aldrich. Drugs were dissolved in dimethyl sulfoxide (DMSO). Prior to drug treatment, cells were plated in six‐well plates. When cells reached 60% confluence, they were treated with indicated drugs for various length of time at the concentration described in corresponding figure legend. After treatment, cells were collected for protein extraction and immunoblotting analysis.

Shao N., Huang H., Idris M., Peng X., Xu F., Dong S, & Liu C. (2020). KEAP1 Mutations Drive Tumorigenesis by Suppressing SOX9 Ubiquitination and Degradation. Advanced Science, 7(21), 2001018.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!